Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -0.13% | -0.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -0.13% | -0.44% | |||
| Cost of Revenue | 27.39% | 17.38% | |||
| Gross Profit | -18.30% | -9.43% | |||
| SG&A Expenses | -7.75% | -51.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.38% | -42.07% | |||
| Operating Income | -8.85% | 72.18% | |||
| Income Before Tax | 73.64% | -188.88% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 73.64% | -188.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 73.64% | -188.88% | |||
| EBIT | -8.85% | 72.18% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 73.53% | -183.33% | |||
| Normalized Basic EPS | -20.00% | 64.29% | |||
| EPS Diluted | 73.53% | -183.33% | |||
| Normalized Diluted EPS | -20.00% | 64.29% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||